Unraveling oxyntomodulin, GLP1's enigmatic brother
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
Oxyntomodulin (OXM) is a peptide secreted from the L cells of the gut following nutrient ingestion. OXM is a dual agonist of the glucagon-like peptide-1 receptor (GLP1R) and the glucagon receptor (GCGR) combining the effects of GLP1 and glucagon to act as a potentially more effective treatment for obesity than GLP1R agonists. Injections of OXM in humans cause a significant reduction in weight and appetite, as well as an increase in energy expenditure. Activation of GCGR is classically associated with an elevation in glucose levels, which would be deleterious in patients with T2DM, but the antidiabetic properties of GLP1R agonism would be expected to counteract this effect. Indeed, OXM administration improved glucose tolerance in diet-induced obese mice. Thus, dual agonists of the GCGR and GLP1R represent a new therapeutic approach for diabetes and obesity with the potential for enhanced weight loss and improvement in glycemic control beyond those of GLP1R agonists.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Biology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639 · cited 1×
“DPP4, among other tissues and cell types, is found on the surface of endothelial Journal of Endocrinology (2012) 215, 335–346 cells of capillaries in the intestinal mucosa adjacent to the sites of GLP1 secretion (Hansen et al. 1999, Baggio & Drucker 2007).”
BackgroundGlycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Kahn, S. E., Haffner, S. M., Heise, M. A., Herman, W. H., Holman, R. R., Jones, N. P., Kravitz, B. G., Lachin, J. M., O'Neill, M. C., Zinman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa066224 · Cited by 2,962
A role for glucagon-like peptide-1 in the central regulation of feeding
Turton, M. D., O'Shea, D., Gunn, I., Beak, S. A., Edwards, C. M. B., Meeran, K., Choi, S. J., Taylor, G. M., Heath, M. M., Lambert, P. D., et al. (1996) · Nature · doi:10.1038/379069a0 · Cited by 1,950
U.K. Prospective Diabetes Study Group (1995) · Diabetes · doi:10.2337/diab.44.11.1249 · Cited by 1,923 · cited 1×
“…of GLP1 and OXM are abolished by co-administration of the GLP1R antagonist, exendin(9–39), and are not observed in Glp1rK/K mice, suggesting that the central effect of OXM is mediated by the GLP1R (Turton et al. 1996, Dakin et al. 2001, Baggio et al. 2004, Sowden et al. 2007, Wynne et al. 2010).”
BackgroundVilsboll, T., Christensen, M., Junker, A. E., Knop, F. K., & Gluud, L. L. (2012) · BMJ · doi:10.1136/bmj.d7771 · Cited by 970
Drucker, D. J., Philippe, J., Mojsov, S., Chick, W. L., & Habener, J. F. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.10.3434 · Cited by 903 · cited 9×
“OXM shows similar functional potencies (EC50, cAMP production) at the GLP1R and GCGR (Baldissera et al. 1988, Gros et al. 1993, Holst 2000, Pocai et al. 2009, Kosinski et al. 2012) at w1–2 orders of magnitude higher than the plasma levels of OXM/OLI reported in postprandial state and then only approach EC50 plasma lev…”
BackgroundInfluentialon behalf of the NN8022-1807 Investigators, Astrup, A., Carraro, R., Finer, N., Harper, A., Kunesova, M., Lean, M. E. J., Niskanen, L., Rasmussen, M. F., Rissanen, A., et al. (2012) · International Journal of Obesity · doi:10.1038/ijo.2011.158 · Cited by 757 · cited 2×
“Nevertheless, protease-resistant GLP1R agonists (Drucker et al. 2010, Htike et al. 2012, Nauck 2012) represent a new class of antihyperglycemic agents that reduce body weight (D’Alessio 2008, Vilsboll et al. 2012) and are currently being tested for the treatment of obesity (Astrup et al. 2012).”
BackgroundKlonoff, D. C., Buse, J. B., Nielsen, L. L., Guan, X., Bowlus, C. L., Holcombe, J. H., Wintle, M. E., & Maggs, D. G. (2008) · Current Medical Research and Opinion · doi:10.1185/030079908x253870 · Cited by 699 · cited 1×
“Thus far, incretin-based therapies (GLP1R agonists and DPP4 inhibitors) are providing durable glycemic control with improved insulin resistance and b-cell function (Klonoff et al. 2008, Derosa & Maffioli 2012, Derosa et al. 2012a,b, van Genugten et al. 2012).”
BackgroundTruncated GLP-1 (proglucagon 78?107-amide) inhibits gastric and pancreatic functions in man
Wettergren, A., Schjoldager, B., Mortensen, P. E., Myhre, J., Christiansen, J., & Holst, J. J. (1993) · Digestive Diseases and Sciences · doi:10.1007/bf01316798 · Cited by 670
Larsen, P. J., Tang-Christensen, M., Holst, J. J., & Ørskov, C. (1997) · Neuroscience · doi:10.1016/s0306-4522(96)00434-4 · Cited by 663
Cited by
Peptide therapeutics: current status and future directions
Fosgerau, K., & Hoffmann, T. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2014.10.003 · Cited by 3,030
Pharmacology, Physiology, and Mechanisms of Action of Dipeptidyl Peptidase-4 Inhibitors
Mulvihill, E. E., & Drucker, D. J. (2014) · Endocrine Reviews · doi:10.1210/er.2014-1035 · Cited by 609
Furness, J. B., Rivera, L. R., Cho, H.-J., Bravo, D. M., & Callaghan, B. (2013) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2013.180 · Cited by 526
Type 2 Diabetes Mellitus: A Review of Multi-Target Drugs
Artasensi, A., Pedretti, A., Vistoli, G., & Fumagalli, L. (2020) · Molecules · doi:10.3390/molecules25081987 · Cited by 494
Insulin resistance and Parkinson’s disease: A new target for disease modification?
Athauda, D., & Foltynie, T. (2016) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.10.001 · Cited by 328
Metadata
- Authors
- Pocai, A.
- Venue
- Journal of Endocrinology
- Publisher
- Bioscientifica
- Published
- 2012-09-27
- Volume
- 215
- Issue
- 3
- Pages
- 335-346
- ISSN
- 0022-0795 (ISSN-L)
- 1479-6805
- OpenAlex
- W2119446720
- Cited by
- 130
- References
- 24
- FWCI
- 8.28
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Unraveling oxyntomodulin, GLP1's enigmatic brother. https://app.cochat.ai/papers/10.1530/joe-12-0368
- The paper
- Pocai, A. (2012). Unraveling oxyntomodulin, GLP1's enigmatic brother. Journal of Endocrinology. https://doi.org/10.1530/joe-12-0368
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.